Fed. Trade Comm'n v. Omics Grp. Inc.

302 F. Supp. 3d 1184
CourtDistrict Court, D. Nevada
DecidedSeptember 29, 2017
DocketCase No.: 2:16–cv–02022–GMN–VCF
StatusPublished
Cited by1 cases

This text of 302 F. Supp. 3d 1184 (Fed. Trade Comm'n v. Omics Grp. Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fed. Trade Comm'n v. Omics Grp. Inc., 302 F. Supp. 3d 1184 (D. Nev. 2017).

Opinion

Gloria M. Navarro, Chief Judge

Pending before the Court is the Motion for Preliminary Injunction, (ECF No. 9), filed by Plaintiff Federal Trade Commission ("the FTC"). Defendants OMICS Group Inc. ("OMICS"), iMedPub LLC ("iMedPub"), Conference Series LLC ("Conference Series"), and Srinubabu Gedela ("Gedela") (collectively "Defendants") filed a response, (ECF No. 32), and the FTC filed a Reply, (ECF No. 34). Also pending before the Court is Defendants' Motion to Dismiss. (ECF No. 31). The FTC filed a response, (ECF No. 35), and Defendants filed a reply, (ECF No. 36). For the reasons discussed herein, the FTC's Motion for Preliminary Injunction is GRANTED and Defendants' Motion to Dismiss is DENIED.

I. BACKGROUND

The FTC brings this action pursuant to Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), alleging that Defendants engaged in unfair and deceptive practices with respect to the publication of online academic journals and organization of scientific conferences. (See Compl., ECF No. 1). Defendants claim to operate hundreds of online academic journals on a wide variety of topics, including medicine, chemistry, nursing, engineering, and genetics. (Mot. for Prelim. Inj. 2:1-12, ECF No. 9; see also Defs.' Mot. to Dismiss 4:21-28, ECF No. 31). According to the FTC, Defendants make numerous misrepresentations regarding the nature and reputation of their journals in order to attract consumers. Id. Furthermore, Defendants allegedly fail to disclose that they charge significant fees in exchange for their publication service. Id. Finally, Defendants allegedly make numerous misrepresentations in connection with the marketing of their scientific conferences. Id.

The FTC asserts that Defendants OMICS, iMedPub, and Conference Series (collectively "Corporate Defendants") have operated as a common enterprise in violating Section 5(a) and therefore are jointly and severally liable. (Compl. ¶ 10). The FTC further asserts that Gedela has "formulated, directed, controlled, had the authority to control, or participated in the acts and practices of the Corporate Defendants that constitute the common enterprise." (Id. ). Based on these allegations, the FTC initiated the instant action and filed the Motion for Preliminary Injunction. (ECF Nos. 1, 9). Specifically, the FTC seeks a preliminary injunction that: (1) restrains Defendants from engaging in deceptive practices with respect to the marketing and sale of *1189academic journal publishing services and scientific conference services; (2) requires Defendants to identify assets and make an accounting of their present financial condition and certain business information; and (3) requires Defendants to preserve records. (Mot. for Prelim. Inj. 2:14-21).

II. LEGAL STANDARD

A) Preliminary Injunction

Under Section 13(b) of the Federal Trade Commission Act ("FTC Act"), the Court may grant the FTC a preliminary injunction "[u]pon a proper showing that, weighing the equities and considering the Commission's likelihood of ultimate success, such action would be in the public interest." 15 U.S.C. § 53(b). Section 13(b) of the FTC Act, therefore, "places a lighter burden on the Commission than that imposed on private litigants by the traditional equity standard." F.T.C. v. Warner Commc'n, Inc. , 742 F.2d 1156, 1159 (9th Cir. 1984). Under this more lenient standard, the FTC need not show irreparable harm; instead, it must only demonstrate (1) that it is likely to succeed on the merits and (2) that the equities weigh in favor of an injunction. Id. at 1160 ; see also F.T.C. v. World Wide Factors , 882 F.2d 344, 346 (9th Cir. 1989).

A court's authority to grant injunctive relief under Section 13(b) includes "all the inherent equitable powers ... for the proper and complete exercise" of the court's equity jurisdiction. F.T.C. v. H.N. Singer, Inc. , 668 F.2d 1107, 1112 (9th Cir. 1982) (citations omitted). One such power is the authority to freeze a defendant's assets. Id. at 1113 ; F.T.C. v. Evans Prods. Co. , 775 F.2d 1084, 1088-89 (9th Cir. 1985). As the Ninth Circuit emphasized in H.N. Singer , an order freezing assets is a form of "ancillary relief" rather than a primary remedy. See 668 F.2d at 1112-13. "Courts have inherent equitable powers to grant ancillary relief, other than a preliminary injunction restraining future violations of the law, when there is no likelihood of recurrence." Evans Prods. , 775 F.2d at 1088. "A party seeking an asset freeze must show a likelihood of dissipation of the claimed assets, or other inability to recover monetary damages, if relief is not granted." Johnson v. Couturier , 572 F.3d 1067, 1085 (9th Cir. 2009).

III. DISCUSSION

A. Likelihood of Success on the Merits

Section 5 of the FTC Act prohibits "unfair or deceptive practices in or affecting commerce." 15 U.S.C. § 45.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fed. Trade Comm'n v. Am. Fin. Benefits Ctr.
324 F. Supp. 3d 1067 (N.D. California, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
302 F. Supp. 3d 1184, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fed-trade-commn-v-omics-grp-inc-nvd-2017.